Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-a2b plus ribavirin

2011 ◽  
Vol 16 (7) ◽  
pp. 1137-1138
Author(s):  
Mayumi Ueyama ◽  
◽  
Mina Nakagawa ◽  
Naoya Sakamoto ◽  
Izumi Onozuka ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interleukin 6 ◽  
Pegylated Interferon ◽  
Hepatitis C Infection ◽  
Resistance To Treatment

Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and Hispanics With Chronic Hepatitis C Infection

2010 ◽  
Vol 44 (2) ◽  
pp. 140-145 ◽  
Author(s):  
Sanjaya K. Satapathy ◽  
Chandra Sekhar Lingisetty ◽  
Shawnette Proper ◽  
Shobhana Chaudhari ◽  
Susan Williams
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
African Americans ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Hepatitis C Infection ◽  
Poor Outcomes

scholarly journals Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C

2012 ◽  
Vol 26 (4) ◽  
pp. 205-210 ◽  
Author(s):  
Kyle J Wilby ◽  
Nilufar Partovi ◽  
Jo-Ann E Ford ◽  
Erica D Greanya ◽  
Eric M Yoshida
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Cost Effective ◽  
Pegylated Interferon ◽  
Future Research ◽  
Genotype 1 ◽  
Hepatitis C Infection ◽  
Manual Search ◽  
Cost Effective Treatment

OBJECTIVE: To summarize and evaluate the published literature pertaining to boceprevir and telaprevir, and to provide clinicians with suggestions for use in patients with chronic hepatitis C infection.METHODS: A standardized search strategy was performed using the MEDLINE, EMBASE, Google Scholar and International Pharmaceuticals Abstracts databases using the search terms “boceprevir”, “telaprevir”, “boceprevir and hepatitis C” and “telaprevir and hepatitis C”. A manual search of references was performed to identify articles missed by the electronic search. Studies were included in the review if they assessed either boceprevir or telaprevir in comparison with standard of care in chronic hepatitis C patients.RESULTS: The studies identified assessed boceprevir and telaprevir in genotype-1 hepatitis C patients. In both treatment-naive and treatment-experienced patients, sustained virological response rates were achieved more often with boceprevir or telaprevir in combination with pegylated interferon and ribavirin compared with pegylated interferon and ribavirin alone. Both medications were well tolerated, with anemia presenting as the most treatment-limiting adverse effect.CONCLUSIONS: Boceprevir and telaprevir will revolutionize the management of hepatitis C genotype 1 patients and will most likely decrease the burden of end-stage disease worldwide. However, current clinical limitations include establishing appropriate and cost-effective treatment durations, and use in special populations such as transplant patients and patients coinfected with HIV. Future research will need to clarify these clinical obstacles to clearly define the role of these agents in hepatitis C management.

Sign in / Sign up

Export Citation Format

Share Document